ICU
SeaStar Medical Holding Corp
NASDAQ · Healthcare · Biotechnology · US
$3.11
+7.24%Oct 5, 2026, 12:00 UTC
SeaStar Medical Holding Corporation entered into definitive agreements on October 2, 2026 for the immediate exercise of outstanding warrants to purchase up to 854,002 shares of common stock at a reduced exercise price of $3.866 per share, raising approximately $3.3 million in gross proceeds.
Source:Oct 2, 2026, 13:43 UTC
SeaStar Medical Holding Corporation announced that a late-breaking abstract on its post-approval SAVE Registry data was accepted for a poster presentation at ASN Kidney Week 2026 in Denver, October 21-25, 2026.
Source:Sep 29, 2026, 12:36 UTC
SeaStar Medical announced that Chief Medical Officer Kevin Chung will present on QUELIMMUNE, its extracorporeal therapy for critically ill pediatric patients with acute kidney injury, at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026.
Source:Aug 12, 2026, 23:58 UTC
SeaStar Medical Holding Corporation expanded adoption of its QUELIMMUNE product to 20 of 50 premier children's hospitals, targeting 25 by year-end.
Source:Aug 12, 2026, 20:05 UTC
SeaStar Medical reported its second quarter 2026 financial results, with net revenue up 82% versus the second quarter of 2025, and added three top-rated children's hospitals to its QUELIMMUNE pediatric acute kidney injury customer base.
Source: